Home › Plasma Cell Cancer
Plasma Cell Cancer clinical trials recruiting in the U.S.
24 studies for Plasma Cell Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX5 studies
- Boston, MA5 studies
- New York City, NY4 studies
- Atlanta, GA4 studies
- Miami, FL3 studies
- Charlotte, NC3 studies
- Durham, NC3 studies
By state
- California3 studies
- Florida4 studies
- Georgia4 studies
- Massachusetts5 studies
- New Jersey3 studies
- New York6 studies
- North Carolina5 studies
- Texas6 studies
Recently updated studies
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06152575A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05055063Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
RecruitingObservational studyHealthy volunteers welcome
Ages 7 to 80 · All sexes · Updated Nov 5, 2026 · NCT00106925ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06518551Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07075510HEME Home Transfusion Program
Recruiting
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06487247Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04822337A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT05651932Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
Recruiting
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT05745285Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Oct 5, 2026 · NCT06066359Rutgers University Study of the Genetics of Blood Cancers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 110 · All sexes · Updated Oct 1, 2026 · NCT07714044Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT04879043Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07426484Delayed Toxicities Post-CAR-T
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT07665307Pre-malignant States to Hematologic Malignancies in Firefighters
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 49 · All sexes · Updated Jul 13, 2026 · NCT06870760Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders
RecruitingPhase 1
Ages 18 to 100 · All sexes · Updated Jun 4, 2026 · NCT06313502A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT07052916Pilot Imaging Study of Leukemia
RecruitingPhase 1
Ages 4 to 80 · All sexes · Updated Apr 23, 2026 · NCT03633955Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
Recruiting
Ages 21 and older · All sexes · Updated Feb 5, 2026 · NCT07390071Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 3, 2025 · NCT06947083Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 10, 2025 · NCT05597345A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 2, 2024 · NCT06271252From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.